Other Clinical Trial - MACE & First Operating Room Systolic NCT03185598

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Details — Status: Completed

Study information
Verified date	March 2019
Source	Peking University First Hospital
Contact	n/a
Is FDA regulated	No
Health authority
Study type	Observational

To find the threshold of First operating room SBP above which MACE risk increases.

To find the threshold of First operating room SBP above which MACE risk increases. By reviewing data from 2012-2017 in PKU first hospital.

Recruitment information / eligibility
Status	Completed
Enrollment	90342
Est. completion date	January 5, 2019
Est. primary completion date	October 1, 2018
Accepts healthy volunteers	No
Gender	All
Age group	18 Years to 100 Years
Eligibility	Inclusion Criteria: - 18-100yr non-cardiac surgery Exclusion Criteria: - missing data file

Locations
Country	Name	City	State
n/a

Sponsors *(1)*
Lead Sponsor	Collaborator
Peking University First Hospital

Outcome
Type	Measure	Description	Time frame	Safety issue
Primary	MACE	major adverse cardiac-cerebral-kidney event	30 days postoperatively